Brief: Pharnext announces R&D agreement with Galapagos
09/03/2017 16:46
March 9 (Reuters) - Pharnext SAS PHARN.PA :
* Announces R&D agreement with Galapagos to generate a new
pipeline of synergistic drug combinations
* Main goal of this agreement is to generate an additional
pipeline of novel synergistic drug combinations in a broad set
of indications
Source text for Eikon: urn:newsml:reuters.com:*:nBw3CLXx5a
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development